─ 53 ─

1) 2) 3) 4) 5) 6)

2013 A-0 Hasegawa J, Nishimura J, Mizushima T, Miyake Y, Kim Min H, Takemoto H, Tamagawa H, Noura S, Fujii M, Fujie Y, Kato T, Miwa H, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M,

Nezu R, Doki Y, Mori M. Neoadjuvant Capecitabine and oxaliplatin (XELOX) combined with

bevacizumab for high-risk localized cancer. Springer. 2014; Published online. 2014 3 Suzuki E, Ikeda M, Okusaka T, Nakamori S, Ohkawa S, Nagakawa T, Boku N, Yanagimoto H, Sato T, Furuse J. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract

cancer. Cancer Chemother Pharmacol. 2013 71 5 1141 - 1146 2013 5 Kubo S, Nakanuma Y, Takemura S, Sakata C, Urata Y, Nozawa A, Nishioka T, Kinoshita M, Hamano G, Terajima H, Tachiyama G, Matsumura Y, Yamada T, Tanaka H, Nakamori S, Arimoto A, Kawada N, Fujikawa M, Fujishima H, Sugawara Y, Tanaka S, Toyokawa H, Kuwae Y, Ohsawa M, Uehara S, Sato KK, Hayashi T, Endo G. Case series of 17 patients with cholangiocarcinoma among young adult workers of a printing company in Japan. J

Hepatobiliary Pancreat Sci. 2014 Jan 13. [Epub ahead of print]

─ 54 ─

Hirao M,Tsujinaka T,Imamura H,Kurokawa Y,Inoue K,Kimura Y,Shimokawa T,Furukawa H . Overweight is a risk factor for surgical site infection following distal gastrectomy for gastric

cancer . Gastric Cancer 2013 ; 16 ( 2 ) : 239 - 244 ( 2013 4 ) Masuzawa T,Takiguchi S,Hirao M,Imamura H,Kimura Y,Fujita J,Miyashiro I,Tamura S,HiratsukaM,Kobayashi K,Fujiwara Y,Mori M,Doki Y . Comparison of Perioperative and Long-term Outcomes of Total and Proximal Gastrectomy for Early Gastric Cancer: A

Multi-institutional Retrospective Study . World J Surg.(E Pub) 2013 ; ( 2013 12 ) Tanaka K,Takiguchi S,Miyashiro I,Hirao M,Yamamoto K,Imamura H,Yanao M,Mori M,Doki Y . Impact of reconstruction method on visceral fat change after distal gastrectomy: Results from a randomized controlled trial comparing Billroth I reconstruction and Roux-en-Y

reconstruction. . Surgery(E Pub) 2013 ; ( 2013 11 ) Hirao M,Takiguchi S,Imamura H,Yamamoto K,Kurokawa Y,Fujita J,Kobayashi K,Kimura Y,Mori M,Doki Y . Comparison of Billroth I and Roux-en-Y reconstruction after distal gastrectomy for gastric cancer: one-year postoperative effects assessed by a multi-institutional

RCT. . Ann Surg Oncol. 2013 ; 20 ( 5 ) : 1591 - 1597 ( 2013 5 ) Ikeda M,Sekimoto M,Takemasa I,Mizushima T,Yamamoto H,Ishii H,Doki Y,Mori M . Feasibility and efficacy study of biweekly irinotecan combined with oral tegafur/uracil in

advanced colorectal cancer . Journal of cancer therapy(WEB) 2013 ; 8 - 14 ( 2013 6 ) Aogi k, Rai Y, Ito Y, Masuda N, Watanabe J, Horiguchi J, Tokudome T, Takashima S. Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines:results of a phase II study in Japan. Cancer Chemother Phamacol 2013;71(6):1427-1433(2013 6 ) Kataoka A, Tokunaga E, Masuda N, Shien T, Kawabata K, Miyashita M. Clinicopathological features of young patients (<35 years of age) with breast cancer in Japanese Breast Cancer Society supported study. Breast Cancer (2013 4 )[E-pub ahead of print] Iwata H, Masuda N, Ohno S, Rai Y, Sato Y, Ohsumi S, Hashigaki S, Nishizawa Y, Hiraoka M, Morimoto T, Sasano H, Saeki T, Noguchi S. A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer. Breast Cancer Research and Treatment

─ 55 ─

2013;139(2):441-451(2013 6 ) Sagara Y, Sato K, Fukuma E, Higaki K, Mizutani M, Osaki A, Takano T, Tokuda Y, Ohno S, Masuda N, Suzuki M, Saeki T. The Efficacy and Safety of FSK0808, Filgrastim Biosimilar. A multicenter, Non-randomized Study in Japanese Patients with Breast Cancer. Japanese Journal of Clinical Oncology 2013;43(9): 865-873(2013 7 ) Toi M, Hirota S, Tomotaki A, Sato N, Hozumi Y, Anan K, Nagashima T, Tokuda Y, Masuda N, Ohsumi S, Ohno S, Takahashi M, Hayashi H, Yamamoto S, Ohashi Y. Probiotic Beverage with Soy Isoflavone Consumption for Breast Cancer Prevention: A Case-control Study. Current Nutrition & Food Science 2013;9(3):194-200(2013 9 ) Cortés J, Swain SM, Kudaba I, Hauschild M, Patel T, Grincuka E, Masuda N, McNally V, Ross G, Brewster M, Mariei JF, Trinh MM, Garg A, Nijem I, Visich J, Lum BL, Baselga J. Absence of pharmacokinetic drug–drug interaction of pertuzumab with trastuzumab and docetaxel. Anticancer Drugs 2013;24(10): 1084-1092(2013 11 ) Ohno S, Chow LWC, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res Treat 2013;142(1): 69-80(2013 11 ) Ueno T, Masuda N, Yamanaka T, Saji S, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Sasano H, Toi M. Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. International Journal of Clinical Oncology (2013 10

) [E-pub ahead of print] Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F. Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG. Breast Cancer (2013

12 ) [E-pub ahead of print]

Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, Pistilli B, Masuda N, Hart L, Melichar B, Dakhil S, Geberth M, Nunzi M, Heng DY, Brechenmacher T, E-Hashimy M, Douma S, Ringeisen F, Piccart M. Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2. Breast Cancer Res Treat (2013

12 )[E-pub ahead of print]

─ 56 ─

Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F . Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG.

Breast Cancer ( 2013 2 )[E-pub ahead of print] Sakai D,Satoh T, Kurokawa Y, Kudo T, Nishikawa K, Oka Y, Tsujinaka T, Shimokawa T, Doki Y, Furukawa H. . A Phase II Trial of Trastuzumab Combined with Irinotecan in Patients with Advanced HER2-positive Chemo-refractory Gastric Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5). . Jpn J Clin Oncol 2013 ; 43 ( 8 ) : 838 -

840 ( 2013 8 ) Fujitani K,Miyashiro I, Mikata S, Tamura S, Imamura H, Hara J, Kurokawa Y, Fujita J, Nishikawa K, Kimura Y, Takiguchi S, Mori M, Doki Y . Pattern of abdominal nodal spread and optimal abdominal lymphadenectomy for advanced Siewert type II adenocarcinoma of the

cardia: results of a multicenter study. . Gastric Cancer 2013 ; 16 ( 3 ) : 301 - 308 ( 2013 7 )

Yoshikawa T,Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, Hirabayashi N, Mikata S, Iwahashi M, Fukushima R, Takiguchi N, Miyashiro I, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J . Induction of a Pathological Complete Response by Four Courses of Neoadjuvant Chemotherapy for Gastric Cancer: Early Results of the Randomized Phase II COMPASS

Trial. . Ann Surg Oncol 2014 ; 21 ( 1 ) : 213 - 219 ( 2014 1 ) Endo S,Takiguchi S, Miyazaki Y, Nishikawa K, Imamura H, Takachi K, Kimura Y, Takeno A, Tamura S, Mori M, Doki Y . Efficacy of endoscopic gastroduodenal stenting for gastric outlet obstruction due to unresectable advanced gastric cancer: A prospective multicenter

study. . J Surg Oncol. 2014; 109 ( 3 ) : 208 - 212 ( 2014 3 Hiura Y,Takiguchi S,Yamamoto K,Kurokawa Y,Yamasaki M,Nakajima K,Miyata H,Fujiwara Y,Mori M.Doki Y . Use of fibrin glue sealant with polyglycolic acid sheets to prevent

pancreatic fistula formation after laparoscopic-assisted gastrectomy. . 2013 ; 43 ( 5 ) : 527 - 533 ( 2013 5 ) Tsujinaka T,Yamamoto K,Fujita J,Endo S,Kawada J,Nakahira S,Shimokawa T,Kobayashi S,Yamasaki M,Akamaru Y,Miyamoto A,Mizushima T,Shimizu J,Umeshita K,Ito T,Doki Y,Mori M . Subcuticular sutures versus staples for skin closure after open gastrointestinal

─ 57 ─

surgery:a phase3,multicentre,open-label,randomised controlled trial . Lancet2013 2013 ; 382 :

1105 - 1112 ( 2013 9 ) Ohta K, Haraguchi N, Kano Y, Kagawa Y, Konno M, Nishikawa S, Hamabe A,Hasegawa S, Ogawa H, Fukusumi T, Uemura M, Nishimura J, Hata T, Takemasa I,Mizushima T, Noguchi Y, Ozaki M, Kudo T, Sakai D, Satoh T, Fukami M, Ishii M,Yamamoto H, Doki Y, Mori M, Ishii H . Depletion of JARID1B induces cellular senescence in human colorectal cancer. . Ann Surg

Oncol 2013 ; 42 ( 4 ) : 1212 - 1218 ( 2013 4 ) Nishikawa S, Konno M, Hamabe A, Hasegawa S, Kano Y, Ohta K, Fukusumi T, SakaiD, Kudo T, Haraguchi N, Satoh T, Takiguchi S, Mori M, Doki Y, Ishii H . Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy . Int J Oncol 2013 ; 42 ( 4 ) : 1437 - 1442

( 2013 4 ) Kano Y, Ishii H, Konno M, Ohta K, Nishikawa S, Fukusumi T, Hamabe A, HasegawaS, Ogawa H, Ozaki M, Noguchi Y, Sakai D, Haraguchi N, Kudo T, Satoh T, Doki Y,Mori M . Cancer stem cells depend on their own niche . Gan To Kagaku Ryoho 2013 ; 40 ( 4 ) : 419 - 423 ( 2013

4 ) Yamamoto H, Oshiro R, Nishimura J, Uemura M, Haraguchi N, Hata T, Takemasa I,Mizushima T, Sekimoto M, Doki Y, Mori M . Low-dose dacarbazine-doxorubicin therapy against

intra-abdominal desmoid tumors . Oncol Rep 2013 ; 29 ( 5 ) : 1751 - 1755 ( 2013 5 ) Haraguchi N,Ishii H,Mimori K,OhtaK,UemuraM,Nishimura J,Hata T,Takemasa I,Mizushima T,Yamamoto H,Doki Y,Mori M . CD49f-positive cell population efficiently enriches colon

cancer-initiating cells. . Int J.of Oncology 2013 ; 43 ( 2 ) : 425 - 430 ( 2013 8 ) Ohtsuka M, Yamamoto H, Masuzawa T, Takahashi H, Uemura M, Haraguchi N,Nishimura J, Hata T, Yamasaki M, Miyata H, Takemasa I, Mizushima T, Takiguchi S,Doki Y, Mori M . C4.4A expression is associated with a poor prognosis ofesophageal squamous cell carcinoma .

Ann Surg Oncol 2013 ; 20 ( 8 ) : 2699 - 2705 ( 2013 8 ) Ohtsuka M, Yamamoto H, Oshiro R, Takahashi H, Masuzawa T, Uemura M, Haraguchi N, Nishimura J, Hata T, Yamasaki M, Takemasa I, Miyata H, Mizushima T, TakiguchiS, Doki Y, Mori M . Concurrent expression of C4.4A and Tenascin-C in tumor cells relates to poor

─ 58 ─

prognosis of esophageal squamous cell carcinoma . Int J Oncol 2013 ; 43 ( 2 ) : 439 - 446 ( 2013

8 ) Takeyama H, Mizushima T, Nakajima K, Uemura M, Haraguchi N, Nishimura J, HataT, Takemasa I, Yamamoto H, Doki Y, Mori M . Metachronous, colitis-associated rectal cancer that developed after sporadic adenocarcinomain an adenoma in a patient with longstanding Crohn's

disease: a case report . World J Surg Oncol(PubMed) ( 2013 11 ) Ogino T, Nishimura J, Barman S, Kayama H, Uematsu S, Okuzaki D, Osawa H,Haraguchi N, Uemura M, Hata T, Takemasa I, Mizushima T, Yamamoto H, Takeda K,Doki Y, Mori M . Increased Th17-inducing activity of CD14+ CD163 low myeloid cells in intestinal lamina propria of patients with Crohn's disease . Gastroenterology 2013 ; 145 ( 6 ) : 1380 - 1391 ( 2013

12 ) Okano M, Yamamoto H, Ohkuma H, Kano Y, Kim H, Nishikawa S, Konno M, KawamotoK, Haraguchi N, Takemasa I, Mizushima T, Ikeda M, Yokobori T, Mimori K, Sekimoto M, Doki Y, Mori M, Ishii H. . Significance of INHBA expression in human colorectal cancer . Oncol

Rep 2013 ; 30 ( 6 ) : 2903 - 2908 ( 2013 12 ) Kagawa Y, Matsumoto S, Kamioka Y, Mimori K, Naito Y, Ishii T, Okuzaki D,Nishida N, Maeda S, Naito A, Kikuta J, Nishikawa K, Nishimura J, Haraguchi N,Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Ishii H, Doki Y,Matsuda M, Kikuchi A, Mori M, Ishii M . Cell cycle-dependent Rho GTPase activity dynamically regulates cancer cell motility and

invasion in vivo . PLoS One 2013 ; e83629 ( 2013 12 ) Takeyama H, Yamamoto H, Yamashita S, Wu X, Takahashi H, Nishimura J,Haraguchi N, Miyake Y, Suzuki R, Murata K, Ohue M, Kato T, Takemasa I, MizushimaT, Ishii H, Mimori K, Doki Y, Mori M . Decreased miR-340 expression in bone marrow is associated with liver

metastasis of colorectal cancer . Mol Cancer Ther(PubMed) 2014 ; ( 2014 1 ) Hiraki M, Nishimura J, Ohtsuka M, Shiomi H, Uemura M, Haraguchi N, Hata T,Hayashi T, Takemasa I, Mizushima T, Isohashi F, Yoshioka Y, Ogawa K, Doki Y, MoriM, Yamamoto H . Impact of stereotactic body radiotherapy on colorectal cancer with distant metastases . Oncol

Rep 2014 ; 31 ( 2 ) : 795 - 799 ( 2014 2 )

─ 59 ─

Kano Y, Ishii H, Konno M, Yamasaki M, Miyata H, Nishikawa S, Hamabe A, OgawaH, Takahashi H, Ohta K, Hasegawa S, Tanaka K, Fukusumi T, Otsuka M, Kawamoto K,Haraguchi N, Fujimoto R, Isobe M, Tomita Y, Matsuura N, Takiguchi S, Mori M, Doki Y . Cells of origin of squamous epithelium, dysplasia and cancer in the head and neck region after bone marrow

transplantation . Int J Oncol 2014 ; 44 ( 2 ) : 443 - 450 ( 2014 2 ) Takeyama H, Hata T, Nishimura J, Nonaka R, Uemura M, Haraguchi N, Takemasa I,Mizushima T, Yamamoto H, Doki Y, Mori M . A novel endoscopic fluorescent clip visible with near-infrared imaging during laparoscopic surgery in a porcine model . Surg

Endosc(PubMed) ; ( 2014 2 ) Munakata K, Uemura M, Takemasa I, Ozaki M, Konno M, Nishimura J, Hata T,Mizushima T, Haraguchi N, Noura S, Ikenaga M, Okamura S, Fukunaga M, Murata K,Yamamoto H, Doki Y, Mori M . SCGB2A1 is a novel prognostic marker for colorectal cancer associated with

chemoresistance and radioresistance . Int J Oncol(PubMed) ; ( 2014 2 ) Yamaoka Y, Yamamura J, Masuda N, Yasojima H, Mizutani M, Nakamori S, Kanazawa T, Kuriyama K, Mano M, Sekimoto M. Primary Chest Wall Abscess Mimicking a Breast Tumor That Occurred after Blunt Chest Trauma: A Case Report. Case Reports in Medicine (2014 ) [E-pub ahead of print]

A-1 10 NOTES

2 3 2013 5 A-2

3. - 14 P. 191 - 195 2013

18 P. 23 - 27 2013

HIV AIDS 4 55 - 57 2013 A-3

─ 60 ─

1 2 NURSING 2013 P. 38 - 41 2013

10

- - 33 7

P. 1125 - 1129 2013 11

HIV 10 2 169 - 173 2013 4

, , , , , , , ,

, ypT0/isypN0 -JBCRG-01, JBCRG-02, JBCRG-03 28(6): P.585-595 2013 12

1 58(13) P.1905-1910 2013

S-1 DocetaxelPaclitaxel 1 40 12 2259 - 2261 2013

11

S-1/Lentinan1 40 12 2200 - 2202 2013

11

2 4 PPG NURSING 2013 81 - 84 2013 10

─ 61 ─

Glasgow Prognostic ScoreGPS) 47 6 171 - 176 2013

12

- -HER2 72 1 191 - 193 2014 1

19 1 67

- 72 2014 1

Addison 38 6 1186 - 1190 2013 12

40 12 2448 - 2450 2013 11

Weekly Paclitaxel 40 12 P. 2118 - 2120 2013 11

A Case of HER2-Positive Advanced Gastric Cancer Successfully Treated with a Combination of Capecitabine, Cisplatin, and Trastuzumab as First-Line Chemotherapy

40 12 P. 2253 - 2255 2013 11

EGFR

─ 62 ─

38 2 P 272 - 278 2013 4

3 9 NURSING 2013 147 - 150 2013 10

2 6 NURSING 2013 90 -

93 2013 10

NURSING 18 6 62 - 75 2013 6

Surgical Site Infection

10 2 161 - 167 2013 4

CPT-11/CDDP 1 40 12 2121 - 2123 2013 11

RFA1 40 12 1825 - 1827 2013 11

(BMI 18.5Kg/ ) 38 4 726 - 731 2013 8

10 6 719 - 724 2013

─ 63 ─

5(1) 17 - 21 2013

6

5(2) 110 - 114 2013 6

A-4

37(2) P.195 206 2014 2

Surgery Frontier 20(2) P120-122 2013 6

67(12) P1735-1740 2013 11

66(10) P959-970 2013 10

Slamon D J HER2Cancer Board 6(1) P.33-43 2013 5

ABC Japan 201228(2 2013 4

NO, ?Cancer Board 6(1) P.55-61 2013 6

THERAPEUTIC RESEARCH 34(8) P.1021-1032 2013 8

─ 64 ─

CLINICIAN 60(622) P.65-74 2013 10

P.281-291 2013 11

HER2 285(5) P.501-509 2013 10

HER2 / HER2 9(4) P.373-380 2013 11

3BEV+PTX

P.110-113 2014 3

2 HER2P.30-35 2014 3

90(10) P.35-40 2013 10

von Recklinghausen1 46 ( 5 P. 342 - 349 2013 5

A-5

25 P62-632014 3

28 (5) 2013 10

2013

─ 65 ─

A-6

T-DM1 Monthly Congress eX-press P.12-13 2013 5

2013 8

2013 7

/ 2014 3

/ 2014 3 B-1 O’Regan R, Ozguroglu M, Andre F, Toi M, Jerusalem GHM, Wilks S, Isaacs C, Xu B, Masuda N, Arena FP, Yardley DA, Yap YS, Mukhopadhyay P, Douma S, El-Hashimy M, Taran T,

Sahmoud T, Lebwohl DE, Gianni L. Phase , randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). ASCO2013, Chicago, USA, 2013

6 Hortobagyi G N, Piccart-Gebhart MJ, Rugo HS, Burris HA, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Provencher L, Masuda N, Dakhil SR, Anderson I, Chen D, Damask A, Huang A, McDonald R, Taran T, Sahmoud T, Baselga J. Correlation of molecular alterations with efficacy of everolimus in hormonereceptor–positive (HR+), HER2-negative advanced

breast cancer: Preliminary results from BOLERO-2. ASCO2013, Chicago, USA, 2013 6 Rugo H, Hortobagyi G, Piccart M, Burris H, Campone M, Noguchi S, Perez A, Deleu l, Shtivelband M, Provencher L, Masuda N, Dakhil S, Anderson l, Chen D, Damask A, Huang A, McDonald R, Taran T, Sahmoud T, Baselga J. Genetic Alterations and Everolimus Efficacy in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: Preliminary Correlative Results From BOLERO-2, Presented at 2013 ASCO Breast Cancer Symposium, San Francisco,

USA, 2013 9 Masuda H. The challenge to overcome TNBC heterogeneity, KYOTO BREAST CANCER

CONSENSUS CONFERENCE 2014 ,Kyoto, 2014 2

─ 66 ─

B-2 Sekimoto M, Ikeda M, Ikenaga M, Nakamori S, Fujitani K, Hirao M, Miyamoto A, Asaoka T. The feasibility and efficacy of the operation for locally recurrent rectal cancer. International

Society of Surgery (ISS/SIC)International Surgical Week ISW2013, Helsinki, Finland, 2013 8

Horise Y, Tsumura R, Sekimoto M, Takiguchi S, Doki Y, Mori M, Miyazaki F, Kawai T,

Nishikawa A. Proposal for a Patient-mounted Master-slave Robot System for Single-incision Laparoscopic Surgery. The 35th Annual International Conference of the IEEE Engineering in

Medicine and Biology Society (EMBC'13), Osaka, Japan, 2013 7 Fukutomi A, Uesaka K, Boku N, Kanemoto H, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S,

Nakamura T, Kanai M, Hirano S, Yoshikawa Y, Ohashi Y. JASPAC 01:Randomized phase trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic

cancer. 49 ASCO 2013 , chicago,USA, 2013 5 Kato K,Igaki H,Ito Y,Mizusawa J,Tsubosa Y,Nakagawa S,Daiko H,Hironaka S,Udagawa H,Hayashi K,Nozaki I,Yano M,Kimura Y,Matsushita H,Abe T,Okabe H,Nakamura K,Fukuda

H,Hirao M,Kitagawa Y . Next Study (JCOG1109):A three-arm randomized phase study comparing preoperative CDD 5-FU(CF)versus ocetaxel CF versus CF-radiation followed by esophagectomy with D2-3 lymphadenectomy for locally advanced esophageal squamous cell

cancer , ASCO , Chicago USA , 2013 5 Ito Y, Noguchi S, Deleu I,Baselga J, Hortobagyi GN, Bachelot D, Masuda N, Pistilli B, Pritchard K I, Iwata H, Gnant M , Eakle JF, Csõszi T, Srimuninnimit V, Puttawibul P, Roila F, Panneerselvam A, Taran T, Sahmoud T, Rugo HS. Incidence, management, and resolution of

noninfectious pneumonitis in BOLERO-2. ASCO2013, Chicago, USA, 2013 6 Ohtani S, Taira N, Kihara K, Hasegawa Y, Sakai T, Iwase T, Masuda N, Fujisawa T, Yanagita Y, Ohsumi S, Higaki K, Yamaguchi T, Iwata H. Analysis of health-related quality of life during neoadjuvant endocrine therapy with letrozole in postmenopausal breast cancer patients: N-SAS

BC06 trial. ASCO2013, Chicago, USA, 2013 6 Ueno T, Masuda N, Saji S, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H,

─ 67 ─

Hisamatsu K, Aogi K, Iwata H, Sasano H, Toi M. Relationship of tumor and stromal autophagy

and endocrine responsiveness in breast cancer tissues. ASCO2013, Chicago, USA, 2013 6

Iwata H, Ohtani S, Fujisawa T, Taira N, Masuda N, Kashiwaba M, Yamamoto Y, Toyama T, Yamaguchi T. N-SAS BC06: A phase III study of adjuvant endocrine therapy with or without chemotherapy for postmenopausal breast cancer patients who responded to neoadjuvant letrozole (LET): The New Primary Endocrine-Therapy Origination Study (NEOS). ASCO2013,

Chicago, USA, 2013 6 Yamamoto N, Yamashiro H, Iwata H, Masuda N, Ohtani S, Takahashi M, Yamazaki K, Kato M, Ohno S, Kuroi K, Yamagami K, Morimoto T, Hasegawa Y, Takano T, Kadoya T, Hosoda M, Abe H, Morita S, Yasuno S, Toi M. Safety of trastuzumab in HER2-positive primary breast cancer in Japan: Initial safety report for the large-scale cohort study (JBCRG C-01). ASCO2013,

Chicago, USA, 2013 6 Yoshida A, Arima N, Nakatsukasa K, Okumura Y, Iwase T, Shien T, Masuda N, Tanaka S, Tanabe M, Tanaka T, Komoike Y, Taguchi T, Nishimura R, Inaji H, Yamauchi H, Ishitobi M. The prognostic impact from the difference of surgical procedure after ipsilateral breast cancer

recurrence. ASCO2013, Chicago, USA, 2013 6 Okumura Y, Nishimura R, Nakatsukasa K, Yoshida A, Masuda N, Tanabe M, Shien T, Arima N, Komoike Y, Taguchi T, Inaji H, Ishitobi M. Changes in the biologic markers between primary tumor and ipsilateral breast tumor recurrence after breast conserving surgery: Discordance and

prognosis. ASCO2013, Chicago, USA, 2013 6 Higaki K, Masuda N, Takano T, Matsunami N, Morimoto T, Ohtani S, Mizutani M, Miyamoto T, Kuroi K, Ohno S, Morita S, Toi M. Phase II study of neoadjuvant chemotherapy with a metronomic regimen of paclitaxel + cyclophosphamide + capecitabine followed by 5-fluorouracil + epirubicin + cyclophosphamide in operable triple-negative breast cancer

(JBCRG-13study). ASCO2013, Chicago, USA, 2013 6 Sato F, Ueno T, Myomoto A, Takizawa S, Masuda N, Aogi K, Kondo N, Mikami Y, Saji S, Toi M. Development of microRNA-based prediction model of trastuzumab treatment response for HER2-positive breast cancer using FFPE specimens. European Breast Cancer Conference,

United Kingdom, 2014 3

─ 68 ─

Nishikawa K,Iwase K,Kawada J,Aono T,Yoshida H,Nomura M,Tamagawa H,Matsuda C,Deguchi T,Higashi S,Deguchi K,Noguchi Y,Okumura Y,Nomura M,Endo S,Tanaka Y . The expression of thymidine phosphorylase correlates with the efficacy of capecitabine and cisplatin

therapy in advanced gastric cancer , IGCC2013 , Verona , 2013 6 Nishikawa K,Yoshikawa T,Ito Y,Tanabe K,Matsui T,Kimura Y,Morita S,Miyashita Y,Tsuburaya A,Sakamoto J . Accuracy of clinical diagnosis after neoadjuvant chemotherapy for

gastric cancer:Exploratoryanalysis of a randomized phase COMPASS trial , IGCC2013 , Verona , 2013 6 Nishikawa K,Aoyama T,Takiguchi N,Tanabe K,Imano M,Fukushima R,Tsuburaya A,Sakamoto

J,Morita S,Kono T . Double-Blind,placebo-controlled,randomized phase study of TJ-14(Hangeshashinto)for gastric cancer chemotherapy-inducedoral mucositis , ESMO2013 ,

Amsterdam , 2013 9 Nishikawa K,Tanabe K,Fujii M,Kunisaki C,Tsuji A,Matsuhashi N,Takagane A,Ohno T,Kawase T,Kochi M,Yoshida K,Kakeji Y,Ichikawa W,Chin K,Terashima M,Takuuchi M,Nakajima T . A

randomized phase trial of second-line chemootherapy comparing CPT-11 alone versus S-1 plus CPT-11 combination therapy in advanced gastric cancer refractory to first-line therapy with

S-1(JACCRO GC-05) , ASCO-GI , San Francisco , 2014 1 Nishikawa K,Kishi K,Inoue K,Matsuyama J,Akamaru Y,Kimura Y,Tamura S,Kawabata R,Kawada J,Fujiwara Y,Kawase T,Fukui J,Takagi M,Takeno A,Shimokawa T,Imamura H . Evaluation of the effects of postoperative oral nutrition support on body weight in gastric cancer

patients by using an elemental diet:A randomized study , ASCO-GI , San Francisco , 2014 1 Asaoka T,Miyamoto A,Yamamoto K,Ikenaga K,Miyazaki M,Omiya H,Hirao M,Ikeda M, Takami K,Fujitani K,Nakamori S,Sekimoto M . SINGLE-INCISION VERSUS CONVENTIONAL LAPAROSCOPIC CHOLECYSTECTOMY , SAGES 2013 , Baltimore ,

2013 4 Asaoka T,Miyamoto A,Yamamoto K,Haraguchi N,Miyake M,Nishikawa K,Hirao M,Ikeda M,Sekimoto M,Nakamori S . PREOPERATIVE NEUTROPHIL-TO-LYMPHOCYTE RATIO

─ 69 ─

(NLR) AND SERUM CA19-9 AS SIGNIFICANT PREDICTORS FOR PANCREATIC HEAD

CANCER , AHPBA2014 , Miami , 2014 2 Yamamoto K,Fujitani K,Hirao M,Sekimoto M . Comparison between esophagogastrostomy and jejunal pouch interposition after proximal gastrectomy for early gastric cancer , IGCC2013 ,

Verona , 2013 6 Yamamoto K,Fujitani K,Hirao M,Kodama Y,Mori K,Sekimoto M . HER2 status concordance between endoscopic biopsy and surgically resected specimen in gastric cancer , IGCC2013 ,

Verona , 2013 6 Yamamoto K,Kurokawa Y,Tsuijinaka T,Muguruma K,Nakai T,Fujita J,Hiramatsu

M,Takabayashi A,Hirota S,Nishida T . Multicentre randomized phase trial of adjuvant imatinib for 6 versus 12 months in patients with intermediate or high risk GIST:Interim analysis

results , ESMO2013 , Amsterdam , 2013 10 Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of

triple-negative breast cancer. ASCO2013, Chicago, USA, 2013 6 Kogawa T, Fouad T, Liu D, Shen Y, Masuda H, Gregor MCM, Alvarez R, Valero V, Hortobagyi

G, Ueno N. Role of HER2 FISH ratios in predicting pathological complete response pCR) to neoadjuvant systemic chemotherapy with trastuzumab in patients with inflammatory breast cancer (IBC) and non-inflammatory locally advanced breast cancer, European Chapter on

Combinatorial Optimization, 2013 10 Yamaoka Y,Ikeda M,Ikenaga M,Haraguchi N,Miyake M,Yamamoto K,Asaoka T,Nishikawa K,Miyamoto A,Miyazaki M,Hirao M,Nakamori S,Sekimoto M . The Impact of Fondaprinux on the Prophylaxis of Venous Thromboembolism:The Efficacy,Safety and Prognosis after

Resection for Colorectal Cancer , 67 Cancer Symposium,Society of Surgical Oncology , Phoenix Arizona USA , 2014 3 Fukuda Y,Fujitani K,Hirao M,Yamamoto K,Sekimoto M . Prognostic factors in patients with resectable gastric neuroendcrine cell carcinoma : a single-center study , IGCC2013 , Verona ,

2013 6

─ 70 ─

B-3

92014 3

72013 8

262013 11

S-1III (JASPAC 01) 68 2013

7

JASPAC 01 51 2013 10

1,2-DCP,DCM 72

2013 10

ESD86 2014 3

VTE113 2013 4

─ 71 ─

VTE 33 2013 6

75 2013 11

VTE 75 2013 11

: 21 20136

: Subtype 21 2013 6

: 201121

2013 6

:

ALDH1 212013 6

: HER2Carboplatin 21 2013 6

: NEOS21 2013 6

Rai Y, Sagara Y, Kuranami M, Masuda N, Takano T, Saeki T, Nakamura S, Ito Y, Tokuda Y,

Tamura K: Primary systemic therapy of breast cancer in the next generation 11

─ 72 ─

, 2013 8

: HER2 11 , 2013 8 Takahashi S, Kashiwaba M, Takao S, Ito Y, Doihara H, Rai Y, Matsubara M, Kanatani K, Masuda N: A Phase 2 Study Trastuzumab Emtansine in Japanese Patients With HER2 Positive

Metastatic Breast Cancer 11 , 2013 8 Iwata H, Masuda N, Aogi K, Xu Y, Ibrahim A, Sasaki Y: A phase lb trial of Ramucirumab(RAM),in combination with docetaxel (D) in Japanese patients with advanced

metastatic breast cancer(MBC) 11 , 2013 8

: HER251 2013 10

: HER2 51 2013 10

: 2013 512013 10

Masuda N, Ito Y, Iwata H, Mukai H, Horiguchi J, Tokuda Y, Kuroi K, Sahmoud T, OhnoN, Noguchi S: Ph III BOLERO-2 study of everolimus plus exemestane: Japanese subgroup

analysis 51 2013 10

: HER2 75 201311

: 752013 11

: HER2 7512 2013 11

─ 73 ─

: 7512 2013 11

HER2 11 2013 8

Stage IV 75 2013 11

ECRIN

TRICS XparTSI) 86 2014 3

461 T1 86 2014 3

113 2013 4

68 2013 7

: Eriblin Trastuzumab 51 201310

: pCR H25 NHO1 2013

11

─ 74 ─

26

2013 11 B-4

3 368 2013 7

262013 11

Stage 792013 7

113

2013 4 Maeda A, Uesaka K, Fukutomi A, Boku N, Kanemoto H, Konishi M, Matsumoto I, Shimizu

Y, Nakamori S, Sakamoto H. JASPAC 01:Randomized phase trial of adjuvant chemotherapy with gemcitabine vs S-1 for resected pancreatic cancer. 11

2013 8

72

2013 10

─ 75 ─

DNA 72 2013 10

113 2013 4

HIV1 30

2013 5

54 2013 11

113

2013 4

Neoadjuvant chemotherapy endpoint:pN stage 113

2013 4

67 2013 6

68 2013 7

68 2013 7

─ 76 ─

68

2013 11

26 2013 11

FDG-PET 113 2013 4

FDG-PET 30 2013 5

1 54 2013 11

113 2013 4

25 2013 6

”no fasting” 68 2013 7

44 2013 7

─ 77 ─

40 2013 8

JDDW2013 2013 10

51 2013 10

75 2013 11

26 2013 11

26 2013 11

: microRNA HER221

2013 6

: 21 2013 6

: Pregnacy-associated breast cancer 21

2013 6

─ 78 ─

: HER2 Capecitabine+Docetaxel XPT X 3 21

2013 6

: RI ICG- 21 2013 6

: 21 2013 6

113 2013 4

TS-1 LTN1 35 2013 5

TS-1 docetaxel paclitaxel 1 35 2013 5

B-1 Roux-Y 38

2013 6

─ 79 ─

5-FU+CDDPDTX+CDGP 67 2013 6

GPS 50 2013 7

68 2013 7

HER2 status 51

2013 10

B-1 26

2013 11

113 2013 4

11 2013 5

/ 25

2013 6

─ 80 ─

68 2013 7

44 2013 7

40 2013 8

26 2013

9

26 2013 9

49

2013 9

A. Tzakis P.Ruiz JDDW2013

2013 10

75 2013 11

─ 81 ─

26 2013

11

113 2013 4

68 2013 7

SI 26 2013 11

GIST 113 2013 4

GIST GIST GIST

68 2013 7

ERAS 29 2014 2

26

2013 11

─ 82 ─

: Bevacizumab Paclitaxel21 2013 6

ER + HER2 - 212013 6

113 2013 4

E-PASS 113 2013 4

1 67 2013 6

E-PASS 68 2013 7

CRP 75

2013 11

X 86 2014 3

─ 83 ─

FDG-PETG-CSF 1 30

2013 5

26 2013 11

1 50

2014 3

-1

50 2014 3

68 2013 7

75 2013 11

Duchenne1 26

2013 11

11 2013 5

:

─ 84 ─

21 2013 6

72 2013 10

51 2013 10

HIV1 75

2013 11

HIV 11 2013 5

2 75 2013 11

26

2013 11

1 50

2014 3

GIST 86 2014 3

─ 85 ─

25 2013 6

: 21 2013 6

44 2013 7

MBLs

194 2013 11

75

2013 11

MBL EN

29 2014 2

86 2014 3

86

2014 3

─ 86 ─

Nuck 75 2013

11

26 2013 11

194 2013 11

UFT 75

2013 11

21 2014 2

NST SSI 29

2014 2

9 86 2014 3

1 99 2014 2

─ 87 ─

1 85

2013 5

H 68

2013 11

: 21 2013 6

B-5

: 19 2013 5

: 79 2013 7

: 3 2013 8

: VTE 57 2013 8

: 27 2013 9

: Core Sumit in 2013 11

: VTE 26 2013 11

: 2013 2013 12

─ 88 ─

: 16 2014

2

: 2014 2

: HER2 Breast Cancer Conference 20132013 4

: 2 Sakura Breast Cancer Consortium 2013 4

: Meet The Expert in 2013 5

: Bevacizumab2013 5

: 2013 5

: key clinical issues -2013-2013 5

: Luminal- 172013 5

: 4 22013 5

: Breast Cancer Hormonal Therapy Symposium 2013 2013 6

: HER2 Meet the expert -HER2 MoA conference-2013 6

─ 89 ─

: Changing treatment for HER2 positive Breast Cancer JAPAN Breast Cancer Expert Meeting in Chicago, 2013 Chicago, USA 2013 6

: HER2 HER2 Conference 20136

: HER2 20137

: Meet the expert in Shizuoka 2013 7

: HER2 Chugai Breast Cancer Conference in CHIBA2013 7

: 305 EMBRACE)/301 Halaven Creating Hope Consortium2013 7

: HER2 16 KBC2013 8

: 2013 8

: 1 Meet the expert in 2013 8

: &QOL 2013 9

: &QOL 2013 9 11

: &QOL 2013 9 19

─ 90 ─

: Luminal- 102013 9

: 2013 9

: 112013 9

: HER2 Breast Cancer Conference 20139

: 1 Meet the expert in 2013 9

: 51 332013 10

: HER2 2 201310

: HER2 Perjeta Chugai Breast Cancer Symposium in Osaka 2013 10

: 201310

: HER2 201310

: HER2 2nd WEB 2013 11

: 2 Meet the expert in 2013 11

─ 91 ─

: 112013 11

: RANMARK Symposium in Osaka 2013 2013 12

: HER2 HER2 2014 1

: SABCS SABCS WEB2013 1

: Pertuzumab, T-DM1 HER2 352014 2

: HER2 Meet The Expert 20142

: 6 2013 12

: The 7th Kinki Breast Cancer Frontier Meeting (KBCFM) 2013 4

: 12013 8

: luminal luminal 22013 8

: 112013 11

: HER22014 HER4 2013 2

─ 92 ─

: -MDACC postdoctoral fellowship - ROUND TABLE DISCUSSION - 2013 2013 4

: 1 2013 8

: LH-Rha 22013 8

: KBCSG-TR Scientific Meeting 5th Premenopausal Breast Cancer 201312

: 130 2013

9

: 28 Fukuoka Breast Cancer Innovators Meeting 2014 1

: Breast Cancer Overview Map meeting 2014 2014 2

: 3 2013 7

: Breast Care Nures 1 20138

B-6

1 56

2013 6

2013 9

─ 93 ─

22 2013 11

21 2013 12

2014 3

2013 4

3 2014 3

: Chinderella 2013 10

: Zoladex Speaker’s meeting 201310

: 1 KBCSG-TR Scientific Meeting 201310

: Chugai Breast Cancer Symposium2013 2013 11

: HER2 2013 11

: HER2 Breast Cancer Forum in Ishikawa 2013 11

HXP XP (TP/DPD) H Pac 3 TV 2013 9

2013 9

─ 94 ─

2013 10

: 21 2013 12

: T4 2014 3

2014 3

2013 9

21 2013 12

2014 3

19 2013 8

: Treatment strategy for premenopausal patients with breast cancer The 11th Breast Cancer Frontier Meeting 2013 11

1 595 2013 9

7 2013 8

─ 95 ─

HIVNOMI 1 593 2013 5

: (DCIS)

2 193 2013 6

44 2013 7

HIV 1 DIC UPDATE in OSAKA 2013 8

2013 10

13 2014 2

HIV SS 1 596

2013 11

: DCIS 112013 11

Nuck 597 2014 1

─ 96 ─

598 2014 3

Outlet obstruction Defecography 38 2013 7

Defecography 98

2013 11

37 2013 11

B-7

: 2013 11 B-8

Colorectal Cancer Frontier Meeting 2014 1

10 - NOTES2013 4

2013in 2013 9

25 2013 5

2013 6

: 32 2014 1

─ 97 ─

: 32 2014 2

: 32 2014 2

: vol.6 2014 3

B-9

2013 10